Wikipedia:Articles for deletion/Medopad


 * The following discussion is an archived debate of the proposed deletion of the article below. Please do not modify it. Subsequent comments should be made on the appropriate discussion page (such as the article's talk page or in a deletion review).  No further edits should be made to this page.

The result was keep. Notability has been established (non-admin closure) SST  flyer  16:26, 4 June 2016 (UTC)

Medopad

 * – ( View AfD View log  Stats )

Promotional article about a non-notable startup. There's a carpet-bomb of references in the article, but looking at about half of them (all I could stomach), they all appear to be obligatory business coverage and/or rehashes of press releases. The first page of search results on Google returns, in order:


 * 1) Their own website
 * 2) This article
 * 3) Facebook
 * 4) Twitter
 * 5) CrunchBase
 * 6) Linkedin
 * 7) A reprint of a press release on an industry website
 * 8) Obligatory coverage of a funding round in a financial publication
 * 9) Metropad employment listings on a jobs board
 * 10) A Wordpress blog

This is not the sort of coverage notable companies get. Related AfD: Articles for deletion/Dan Vahdat. -- RoySmith (talk) 15:08, 28 May 2016 (UTC)


 * delete article about company that fails Notability criteria;; existence of the article is promotional. Jytdog (talk) 19:45, 28 May 2016 (UTC)

Keep per the significant coverage in reliable sources.  The article notes: "In a first of its kind, an app (developed by BMI Healthcare and Medopad, London, UK) was built on a specially designed Apple watch to be worn by patients receiving chemotherapy drugs and launched in April, 2015, at the King's College NHS Foundation Trust. Drug consumption, side-effects, and symptoms can all be recorded simply by tapping the watch touchscreen, in real time, 24 h a day. The information is transmitted to a hospital-based integrated mobile operating system platform sold by Medopad, potentially stored into electronic records, and carried to mobile devices of physicians. ... Some hospitals, including East Kent Hospital (Canterbury, UK) and Jinan University Hospital (Jinan, China) already use the Medopad platform, making it simple to test these watches."  The article notes: "With Medopad in place, doctors will be able to refer cases to one another for a second opinion from within the app suite. Photos of a patient’s visible symptoms can be taken using an iPad and shared, for example. Another Medopad app features integration with the Google Glass headset, which allows up to five clinicians to collaborate in real time, take pictures and share them, and access a patient’s records simultaneously. A pathology app can even do some analytical work for doctors, with abnormal blood-test results flagged automatically. ... Others worry that Medopad’s impact will not be of universal benefit. Carl Reynolds, CEO of Open Health Care UK, would prefer it if more software developers were commissioned to work with hospital data. That would mean that apps viewable on multiple devices could be created and that hospitals wouldn’t have to buy into a single platform. Medopad will cost about £50 to £90 per month per user for a hospital to license."  The article notes: "One of the most outstanding healthcare startups on the HealthTech/IoT marketplace of the New Horizons 2014 event was Medopad. Medopad allows hospitals, pharmaceuticals and insurance companies to pool their patient data into a single platform so it becomes available to clinicians on apps and mobile devices in real-time. With their headquarters in London, the company was recently valued at 75+ million dollars. I spoke to Dan Vàhdat, CTO of Medopad, on their recent growth and developments. Since the New Horizons event last November things really took off for Medopad. With some major accomplishments in the last six months, there is enough to celebrate for Dan and CEO Dr. Rich Khatib. Though they operate in a market which is relatively hard for startups to get sufficient traction, Medopad managed to realize the following key milestones in the last months:"  The article notes: "London-based Medopad was founded in 2011 by Dr Rich Khatib and Dan Vahdat, engineers who both had experience of developing clinical technology applications. Medopad works by collecting all data from hospital databases and collating them into a central source, which doctors can quickly scan from an iPad. ... The company is a supplier to both the NHS and private healthcare provider BMI Healthcare. It also has offices in the US, Germany and Dubai, as the firm looks to target new markets."  The article notes: "Another company presenting at the Digital Health Innovation Lab was Medopad, which is a mobile health platform that aims to deliver clinical information directly to doctors, wirelessly. With Medopad, a doctor can access patient records, images and lab results on a tablet, rather than having to physically go to the lab or comb through a patient's physical file. What this means is that the doctor can spend more time with the patient, rather than filling out forms and ticking boxes. Essentially, it enables the physician to access all the data he or she needs immediately, saving time and reducing risks of making the wrong decision based on an incomplete view of the patient's data. The company also has a patient monitoring solution, which connects patient devices - such as the Apple Watch, a self-monitoring watch that collects data on the daily activity of the wearer - with their clinical teams."  The article notes: "Medopad is a British healthcare company which has been building apps for doctors since the launch of the iPad. Now with the Apple Watch, it is looking to really improve patients' lives and empower them to get involved in their treatment with tech's latest toy. ... As for the future, Medopad is looking to roll out the trial to other hospitals. Khatib's goal is for all the hospitals in London to be on the scheme and there are plans to work with private hospitals in other countries such as China." <li> The article notes: "Medopad 'We’re facing an ageing population, chronic disease and the rising cost of healthcare,' says Rich Khatib, CEO of mobile healthcare platform Medopad. 'With that comes more data than ever before -- and this is where mobile health comes in to deliver better care and save money.' Medopad enables care providers to access more than 50 million primary care records, check treatment plans and view lab results. It brings vital patient data to doctors and guarantees that all information is encrypted. Medopad was voted the Best Healthcare App 2014 by MEDICA. 'It’s our vision and dream to be the holy grail of healthcare,' Khatib says."</li> </ol>There is sufficient coverage in reliable sources to allow Medopad to pass Notability, which requires "significant coverage in reliable sources that are independent of the subject". Cunard (talk) 04:16, 29 May 2016 (UTC) </li></ul>
 * <small class="delsort-notice">Note: This debate has been included in the list of Technology-related deletion discussions. Lemongirl942 (talk) 09:25, 29 May 2016 (UTC)
 * <small class="delsort-notice">Note: This debate has been included in the list of Medicine-related deletion discussions. Lemongirl942 (talk) 09:25, 29 May 2016 (UTC)
 * <small class="delsort-notice">Note: This debate has been included in the list of Companies-related deletion discussions. Lemongirl942 (talk) 09:25, 29 May 2016 (UTC)


 * Delete. Nothing here but corporate PR. Xxanthippe (talk) 22:23, 29 May 2016 (UTC).
 * Comment: I looked at the current version of the article and do not see any promotional wording. The article is neutrally written and contains citations to the peer-reviewed journal The Lancet Oncology and the magazine the New Scientist that both discuss Medopad in detail. I have found several more reliable sources that I've listed above. This is not the sort of coverage notable companies get – based on the sources I've listed here, I cannot agree with this statement. existence of the article is promotional – how is the article's mere existence promotional? I've reviewed the article and don't find it promotional. But if there is anything promotional currently in the article, please explain so I can rectify the issue.  Nothing here but corporate PR. – I think it's very difficult for "corporate PR" to get into the peer-reviewed journal The Lancet Oncology or the magazine the New Scientist. The New Scientist has negative material about Medopad so is not "corporate PR": "Others worry that Medopad’s impact will not be of universal benefit. Carl Reynolds, CEO of Open Health Care UK, would prefer it if more software developers were commissioned to work with hospital data. That would mean that apps viewable on multiple devices could be created and that hospitals wouldn’t have to buy into a single platform. Medopad will cost about £50 to £90 per month per user for a hospital to license."  Cunard (talk) 17:25, 30 May 2016 (UTC)
 * Keep - there have been clear COI issues with this article in the past, but it has been cleaned up and could be expanded using the sources identified by, which clearly demonstrate notability. Cordless Larry (talk) 19:36, 30 May 2016 (UTC)
 * Delete as I looked at both the article itself and also the listed sources here with none of it actually being convincingly better. SwisterTwister   talk  21:22, 30 May 2016 (UTC)
 * I'm struggling to understand that sentence, . Are you arguing that the sources listed above do not establish the topic's notability? Cordless Larry (talk) 21:32, 31 May 2016 (UTC)

<div style="margin: auto 2em; border: 1px dashed #AAAAAA; padding: 4px; background-color: white; padding-left: 1em;"> References
 * Keep – The article would benefit from some copy editing, but the company meets WP:CORPDEPTH. See source examples below, which are not "corporate PR". North America1000 10:42, 2 June 2016 (UTC)
 * The Lancet
 * The Telegraph
 * New Scientist


 * The above discussion is preserved as an archive of the debate. Please do not modify it. Subsequent comments should be made on the appropriate discussion page (such as the article's talk page or in a deletion review). No further edits should be made to this page.